Shionogi & Co., Ltd.
1-8, Doshomachi 3-chome
Chuo-ku
Osaka 541-0045
Japan
81 6 6202 2161
https://www.shionogi.com
版塊: Healthcare
行業: Drug Manufacturers - Specialty & Generic
全職員工: 4,959
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Isao Teshirogi Ph.D. | CEO, President & Representative Director | 1.88M | 無 | 1959 |
| Susumu Mitsumori | Vice President of Finance & Accounting Department | 無 | 無 | 無 |
| Dr. Ryuichi Kiyama Ph.D. | Senior Executive Officer & Senior VP of Administration Division | 無 | 無 | 無 |
| Mr. Takeshi Shiota Ph.D. | Corporate Officer and Senior VP of Corporate Quality Assurance, Ethics & Compliance Management Div. | 無 | 無 | 無 |
| Mr. Yoshimasa Kyokawa | Vice President of Corporate Communications & Secretary Office | 無 | 無 | 無 |
| Yoshihiro Furuya | Vice President of General Marketing and Compliance Officer of Corporate GXP Compliance Office | 無 | 無 | 無 |
| Mr. Kohji Hanasaki Ph.D. | Senior Executive Officer and Senior VP of Supply Supervisory Unit | 無 | 無 | 無 |
| Dr. John A. Keller Ph.D. | Senior Executive Officer and Senior VP of R&D Supervisory Unit | 無 | 無 | 1965 |
| Mr. Kazuhiro Hatanaka | Senior Executive Officer & Senior VP of Corporate Strategy Division | 無 | 無 | 無 |
| Akira Kato Ph.D. | Senior Executive Officer & President of Shionogi Pharma Co., Ltd | 無 | 無 | 無 |
描述
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19. In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer's disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for head and neck squamous cell carcinoma; S-005151 for Acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for cutaneous ulcer; and S-723595 for type 2 diabetes. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.
公司管治
截至 2024年6月1日 止，Shionogi & Co., Ltd. 的 ISS 管治質素評分為 1。 Pillar 分數正在審核中：1；董事會：1；股東權利：1；現金賠償：1。
